Breaking News

Crucell, Talecris Biotherapeutics Sign License Agreement

Crucell has signed an exclusive, commercial license agreement with NC-based Talecris Biotherapeutics for an undisclosed protein to be produced using the PER.C6 cell line. Crucell will receive an upfront payment of $2.5 million and will be eligible for milestone payments of approximately $30 million across multiple indications. Further details were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters